Real-World data may reveal which breast cancer subtype responds best to CDK4/6 inhibitors

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whether the subtype of their cancer affected how well the drugs worked. By comparing real-world outcomes, researchers hope to learn which patients benefit most from these targeted therapies.